AAN 2024: Pharma Two B’s P2B001 shows promise in early PD

At the American Academy of Neurology (AAN) 2024 Annual Meeting, Pharma Two B presented new safety and tolerability data for P2B001 (pramipexole ER and rasagiline ER 0.6mg/0.75mg) from its Phase II and Phase III clinical trials in Parkinson’s disease (PD) patients.